Instrument Inactif

Autres langues Zalicus Inc Nasdaq

Actions

US98887C1053

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

2016	Transcript : EPIRUS Biopharmaceuticals, Inc., Q4 2015 Earnings Call, Mar 15, 2016
2015	Transcript : EPIRUS Biopharmaceuticals, Inc., Q3 2015 Earnings Call, Nov 16, 2015

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	09/10/18
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	31/01/18
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	19/01/18
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.	18/01/18
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.	11/12/17
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	19/09/16
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index	05/08/16
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index	03/08/16
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations	25/07/16
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy	25/07/16
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination	01/07/16
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..	30/06/16
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.	14/06/16
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes	09/05/16
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	29/03/16
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	15/03/16
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)	09/02/16
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015	16/11/15
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	16/11/15
EPIRUS Biopharmaceuticals, Inc. Appoints Vincent E. Aurentz as Chief Business Officer	10/11/15

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Zalicus Inc Nasdaq

Actions

US98887C1053

Autres langues

Filtres